In a regulatory filing, Halozyme (HALO) said, “On October 1, 2025, Cortney Caudill was appointed as Senior Vice President, Chief Operating Officer of Halozyme Therapeutics, effective immediately. Caudill has served as the company’s Senior Vice President, Chief Operations Officer since October 2023. Prior to joining the company, from 2019 to October 2023, Ms. Caudill served in roles with increasing responsibility at Aeglea Biotherapeutics, Inc., a biotechnology company, including Vice President of Manufacturing, Senior Vice President, Technical Operations and most recently as Chief Product Officer. From 2002 to 2018, she held operational roles of increasing responsibility at various life sciences companies such as Cambrex Bioscience, Vaxagen, Inc., Genentech, Vetter Pharma International, Samsung Biologics, Baxalta and Eaulife NA. She received her B.S. degree in biology and her B.A degree in psychology from the University of Texas.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Announces Merger Agreement with Elektrofi
- Halozyme’s Strategic Expansion and Financial Growth: Buy Rating Affirmed
- Halozyme price target raised to $90 from $85 at H.C. Wainwright
- Nike reports Q1 beat, U.S. takes 5% stake in Lithium Americas: Morning Buzz
- Halozyme Acquires Elektrofi to Enhance Drug Delivery